Market Overview

Amgen, Mass General, Broad Institute Collaborate on New Drugs for IBD


Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ: AMGN) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists with expertise in clinical medicine, IBD biology, human genetics, genomic technology, and drug discovery to work together to help create a new world of therapeutic options for IBD patients.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (AMGN)

View Comments and Join the Discussion!

UPDATE: Nomura Initiates Coverage on AOL

Celsion Announces $15M At-The-Market Registered Direct Offering